Division 5.2 Specific requirements for gene therapy medicinal productsF1F2 United Kingdom Original text. Later amendments are not shown. 5.2.1Human pharmacokinetic studies 5.2.2Human pharmacodynamic studies 5.2.3Safety studies Annotations Textual amendments F1 Substituted by Commission directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (Text with EEA relevance). F2 Substituted by Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products (Text with EEA relevance). ← Division 5.1.8 Division 5.2 Division 5.2.1 →